Immunitybio Inc (IBRX) 13F Holdings Overview (Q2 2026)

IBRX ranks #1491 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

411 institutions disclose a position in IBRX, but none treat it as a major bet — even Great Point Partners LLC, its most concentrated holder, allocates just 5.0% of its own portfolio to it.

California State Teachers Retirement System has added to its IBRX position for two straight quarters, increasing it by $410.0M to reach $410.7M today.

Sculptor Capital LP has trimmed its IBRX position for two straight quarters, cutting it by $1.1M while still holding $1.4M.

IBRX is down 1% today, but institutions show net buying of $375.6M this quarter — a divergence between today's price move and the underlying institutional flow.

IBRX reported a net loss of $992.4M over the trailing twelve months.

• Not yet profitable — net loss of $992.4M over the trailing twelve months
• Revenue grew 192.9% year over year
• Net income declined year over year, from -$367.1M to -$992.4M
• Operating cash flow was negative, using $304.9M in cash